Hashish Bioscience Fights to Come with Longtime Affected person as Witness in DEA Rescheduling Listening to

[PRESS RELEASE] – HOUSTON, Dec. 16, 2024 – Hashish Bioscience Global Holdings (CBIH) continues its unwavering advocacy for hashish as a valid drugs by way of officially petitioning to have Alexis Bortell, long-time hashish recommend and affected person, function a witness within the upcoming Drug Enforcement Management (DEA) listening to on marijuana rescheduling.

Bortell has been a number one voice within the struggle for scientific hashish get admission to since being identified with intractable epilepsy on the age of seven. After enduring years of useless remedies with typical antiepileptic medication, her final choices had been: Felbatol (Felbamate), a drug with severe and doubtlessly life-threatening unwanted side effects, together with dependency and abuse, or a lobectomy, an invasive mind surgical operation with the chance of devastating results corresponding to reminiscence loss, impaired motor serve as, and emotional issues.

In the end, she discovered lasting reduction via a aggregate of CBD and THC, a remedy that has saved her seizure-free for just about a decade. Her tale underscores the tragic have an effect on of hashish’ Agenda I classification, which perpetuates stigma that has significantly restricted her occupation alternatives in scientific college because of drug assessments, dictates the place she will have to reside, and creates totally needless limitations to getting access to her life-saving drugs.

“Alexis’ tale is the explanation why this reclassification must occur. From adolescence to youth, Alexis has confronted inconceivable struggling,” CBIH R&D Director Rosangel Andrades stated. “Shouldn’t our society prioritize protective its youngsters and early life relatively than forcing them to struggle for his or her proper to live to tell the tale? The stigma of a Agenda I classification no longer simplest denies get admission to to crucial drugs but additionally criminalizes those that search to reside more fit, fuller lives.”

CBIH Treasurer and Director John Jones stated, “We are hoping the pass judgement on will acknowledge Alexis as CBIH’s witness for the DEA Hearings, as her private adventure is a compelling testomony to the plain scientific advantages of hashish. Her revel in obviously demonstrates that hashish can now not be categorized as a Agenda I drug, which inaccurately claims it has no confirmed scientific use.”

This second marks a huge bankruptcy in historical past, and we will have to upward push to satisfy it. On the upcoming listening to, with testimonies scheduled to run from Jan. 21 via March 6, the CBIH targets to focus on the real-world penalties of hashish prohibition on sufferers and their households. Bortell’s testimony may just function a profound reminder of the human price of old-fashioned insurance policies and the essential want for significant reform.